<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDROXYUREA- hydroxyurea capsule </strong><br>Barr Laboratories Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use hydroxyurea capsules USP safely and effectively.  See full prescribing information for hydroxyurea capsules USP.<br>HYDROXYUREA capsules, for oral use<br>Initial U.S. Approval: 1967</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Indications and Usage, melanoma (<a href="#ID_e42bcdd1-5c1a-42b1-8c96-7789a143989f">1</a>) Removed 7/2015<br>Indications and Usage, carcinoma of the ovary (<a href="#ID_e42bcdd1-5c1a-42b1-8c96-7789a143989f">1</a>) Removed 7/2015<br>Dosage and Administration (<a href="#ID_f50a22a1-2c84-4c89-8136-db224723d81a">2</a>) 7/2015 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Hydroxyurea Capsules USP are an antimetabolite indicated for the treatment of: </p>
<dl>
<dt>•</dt>
<dd>Resistant <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span>. (<a href="#ID_e42bcdd1-5c1a-42b1-8c96-7789a143989f">1</a>)</dd>
<dt>•</dt>
<dd>Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation. (<a href="#ID_e42bcdd1-5c1a-42b1-8c96-7789a143989f">1</a>)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Individualize treatment based on tumor type, disease state, response to treatment, patients risk factors, and current clinical practice standards. (<a href="#ID_b5bd9b3f-a25b-4c51-9254-da712b869094">2.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Reduce the dose of hydroxyurea capsules by 50% in patients with creatinine clearance less than 60 mL/min. (<a href="#ID_25535eeb-7735-4a2e-a6c1-0b8474a634d7">2.3</a>, <a href="#ID_58743593-2210-41c0-aaf8-a7480ec8daaf">8.6</a>, <a href="#ID_1dced693-5a21-4167-b7b4-6df5fe635fa3">12.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Capsules: 500 mg (<a href="#ID_1b0e5ac8-a46b-4126-8e08-38e8532d2d8d">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>In patients who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydroxyurea or any other component of its formulation. (<a href="#ID_3a702c79-83e6-410c-96fd-331ecda88cef">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>: Do not give if bone marrow function is markedly depressed. Monitor hematology labs and interrupt, reduce dose as appropriate. (<a href="#ID_8cf8d7bb-eead-414c-ad39-5bdec54690f5">5.1</a>) </dd>
<dt>•</dt>
<dd>Malignancies: Advise protection from sun exposure and monitor for secondary malignancies. (<a href="#ID_ffff24db-cd61-4c2c-8e2c-a48e7769dcaf">5.2</a>) </dd>
<dt>•</dt>
<dd>Embryo-fetal toxicity can cause fetal harm Advise of potential risk to a fetus and use of effective contraception. (<a href="#ID_4a7508a5-d905-4bb7-a0c6-35bd5ea4d212">5.3</a>, <a href="#ID_774fe160-e26e-48e2-8aa3-27c7a102b02a">8.1</a>) </dd>
<dt>•</dt>
<dd>Vasculitic toxicities: Discontinue hydroxyurea and initiate alternative management if this occurs. (<a href="#ID_cc4f0ff7-91b9-43da-a0fb-bb66711b6a4e">5.4</a>) </dd>
<dt>•</dt>
<dd>Risks with concomitant use of antiretroviral drugs: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, hepatotoxicity, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> have occurred. Monitor for signs and symptoms in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> using antiretroviral drugs; discontinue hydroxyurea, and implement treatment. (<a href="#ID_e8331670-7dd8-4a03-bf7e-7dceddc202cf">5.5</a>) </dd>
<dt>•</dt>
<dd>Radiation recall: Monitor for <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span> in patients who previously received radiation and manage symptomatically. (<a href="#ID_5feef2e2-7a80-4d8e-8158-21bd42b4a3fe">5.6</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥30%) are hematological, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. (<a href="#ID_ec7bf2aa-99ab-494b-94f9-9c7a929370f3">6</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Antiretroviral drugs (<a href="#ID_c8dd47b0-de65-4fce-b62c-610c62668bae">7</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Nursing Mothers: </span>Hydroxyurea is excreted in human milk. Discontinue nursing during treatment with hydroxyurea. (<a href="#ID_8b944199-fd11-473b-b591-9a75982add06">8.3</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Geriatric Use: </span>Care should be taken in dose selection and may require a lower dose regimen and monitoring of renal function. (<a href="#ID_e8b6ccf0-5c21-49e9-99cb-a1f9948e99dd">8.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Modifications for Toxicity</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Modifications for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Malignancies </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Embryo-Fetal Toxicity </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Vasculitic Toxicities </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Risks with Concomitant Use of Antiretroviral Drugs </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Radiation Recall </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span> </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Test Interference  </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers </a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use </a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>  </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION </a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action </a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES </a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied </a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage </a></h2>
<h2><a href="#section-14.3" class="toc">16.3 Handling and Disposal </a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<h2><a href="#section-16.1" class="toc">Hydroxyurea Capsules USP 500 mg 100s Label Text </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_e42bcdd1-5c1a-42b1-8c96-7789a143989f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE </h1>
<p class="First">Hydroxyurea Capsules USP are indicated for the treatment of:</p>
<dl>
<dt>•</dt>
<dd>Resistant <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myeloid leukemia</span>.</dd>
<dt>•</dt>
<dd>Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_f50a22a1-2c84-4c89-8136-db224723d81a"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b5bd9b3f-a25b-4c51-9254-da712b869094"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">Hydroxyurea is used alone or in conjunction with other antitumor agents or radiation therapy to treat neoplastic diseases. Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical practice standards.</p>
<p>Base all dosage on the patient’s actual or ideal weight, whichever is less.</p>
<p>Hydroxyurea is a cytotoxic drug. Follow applicable special handling and disposal procedures [<span class="Italics">see References (<a href="#ID_4736cd56-1d67-4863-9798-868a6e917de0">15</a>)</span>].</p>
<p><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> administration of folic acid is recommended <span class="Italics">[see Warnings and Precautions (<a href="#ID_7d61d67f-8a3b-4c9a-9882-69717ec1b859">5.7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_21452f16-b284-45fe-ad45-951c05aead37"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Modifications for Toxicity</h2>
<p class="First">Monitor for the following and reduce the dose or discontinue hydroxyurea accordingly:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_8cf8d7bb-eead-414c-ad39-5bdec54690f5">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">Cutaneous vasculitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_cc4f0ff7-91b9-43da-a0fb-bb66711b6a4e">5.4</a>)]</span>
</dd>
</dl>
<p>Monitor blood counts at least once a week during hydroxyurea therapy. Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> must be corrected before initiating therapy with hydroxyurea. Consider dose modifications for other toxicities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_25535eeb-7735-4a2e-a6c1-0b8474a634d7"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Modifications for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Reduce the dose of hydroxyurea by 50% in patients with measured creatinine clearance of less than 60 mL/min or with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) <span class="Italics">[see Use in Specific Populations (<a href="#ID_58743593-2210-41c0-aaf8-a7480ec8daaf">8.6</a>) and Clinical Pharmacology (<a href="#ID_1dced693-5a21-4167-b7b4-6df5fe635fa3">12.3</a>)]</span>.</p>
<table width="100%">
<col width="38%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Creatinine Clearance</span></p>
<p><span class="Bold">(mL/min)</span></p>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Recommended Hydroxyurea Initial Dose</span></p>
<p><span class="Bold">(mg/kg daily)</span></p>
</td>
</tr>
<tr>
<td class="Toprule" align="center" valign="top"><p class="First">≥60</p></td>
<td class="Toprule" align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top"><p class="First">&lt;60 or ESRD*</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">7.5</p></td>
</tr>
</tbody>
</table>
<p>* On dialysis days, administer hydroxyurea to patients following hemodialysis.</p>
<p>Close monitoring of hematologic parameters is advised in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_1b0e5ac8-a46b-4126-8e08-38e8532d2d8d"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">Capsules: 500 mg purple opaque cap and pink opaque body imprinted in black ink <span class="Bold">barr 882</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_3a702c79-83e6-410c-96fd-331ecda88cef"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<p class="First">Hydroxyurea is contraindicated in patients who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydroxyurea or any other component of the formulation.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_9fd182b2-e8f6-41ce-8ca3-9cfc7c60ca37"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8cf8d7bb-eead-414c-ad39-5bdec54690f5"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> </h2>
<p class="First">Hydroxyurea causes severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Treatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> is generally its first and most common manifestation. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occur less often and are seldom seen without a preceding <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone marrow depression</span> is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; use hydroxyurea cautiously in such patients. </p>
<p>Evaluate hematologic status prior to and during treatment with hydroxyurea. Provide supportive care and modify dose or discontinue hydroxyurea as needed. Recovery from <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is usually rapid when therapy is interrupted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ffff24db-cd61-4c2c-8e2c-a48e7769dcaf"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Malignancies </h2>
<p class="First">Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for <span class="product-label-link" type="condition" conceptid="4175485" conceptname="Myeloproliferative disorder">myeloproliferative disorders</span>, secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> has been reported. Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4a7508a5-d905-4bb7-a0c6-35bd5ea4d212"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Embryo-Fetal Toxicity </h2>
<p class="First">Hydroxyurea may cause fetal harm when administered to a pregnant woman. Hydroxyurea is genotoxic. Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m<span class="Sup">2</span> basis. Hydroxyurea is embryotoxic and causes <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> at 180 mg/kg/day in rats and at 30 mg/kg/day in rabbits. Single doses of ≥375 mg/kg to rats caused <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and impaired learning ability. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during and after treatment with hydroxyurea for at least 30 days after therapy. Females of reproductive potential should also ensure that their male partner, who is/has taken hydroxyurea, uses effective contraception during and after treatment for at least 1 year after therapy. Advise males of reproductive potential to use effective contraception during and after treatment with hydroxyurea for at least 1 year after therapy <span class="Italics">[see Use in Specific Populations (<a href="#ID_774fe160-e26e-48e2-8aa3-27c7a102b02a">8.1</a>, <a href="#ID_8b944199-fd11-473b-b591-9a75982add06">8.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cc4f0ff7-91b9-43da-a0fb-bb66711b6a4e"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Vasculitic Toxicities </h2>
<p class="First">Cutaneous vasculitic toxicities, including vasculitic ulcerations and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>, have occurred in patients with <span class="product-label-link" type="condition" conceptid="4175485" conceptname="Myeloproliferative disorder">myeloproliferative disorders</span> during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. If cutaneous vasculitic <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> occur, institute treatment and discontinue of hydroxyurea.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e8331670-7dd8-4a03-bf7e-7dceddc202cf"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Risks with Concomitant Use of Antiretroviral Drugs </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, hepatotoxicity, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> have occurred when hydroxyurea was administered concomitantly with antiretroviral drugs, including didanosine and stavudine <span class="Italics">[see Drug Interactions (<a href="#ID_235485ba-dc36-4583-b320-e58bc6ffb1bc">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5feef2e2-7a80-4d8e-8158-21bd42b4a3fe"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Radiation Recall </h2>
<p class="First">Patients who have received irradiation therapy in the past may have an exacerbation of postirradiation <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>. Monitor for <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span> in patients who previously received radiation and manage symptomatically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d61d67f-8a3b-4c9a-9882-69717ec1b859"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span> </h2>
<p class="First">Hydroxyurea may cause <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>, which is self-limiting, and is often seen early in the course of treatment. The morphologic change resembles <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>, but is not related to vitamin B<span class="Sub">12</span> or <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span>. This may mask the diagnosis of <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> administration of folic acid is recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_ec7bf2aa-99ab-494b-94f9-9c7a929370f3"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">The following adverse reactions are described in detail in other labeling sections:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_8cf8d7bb-eead-414c-ad39-5bdec54690f5">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Malignancies <span class="Italics">[see Warnings and Precautions (<a href="#ID_ffff24db-cd61-4c2c-8e2c-a48e7769dcaf">5.2</a>)]</span>
</dd>
<dt>•</dt>
<dd>Embryo-fetal toxicity <span class="Italics">[see Warnings and Precautions (<a href="#ID_4a7508a5-d905-4bb7-a0c6-35bd5ea4d212">5.3</a>)]</span>
</dd>
<dt>•</dt>
<dd>Vasculitic toxicities <span class="Italics">[see Warnings and Precautions (<a href="#ID_cc4f0ff7-91b9-43da-a0fb-bb66711b6a4e">5.4</a>)]</span>
</dd>
<dt>•</dt>
<dd>Risks with concomitant use of antiretroviral drugs <span class="Italics">[see Warnings and Precautions (<a href="#ID_e8331670-7dd8-4a03-bf7e-7dceddc202cf">5.5</a>)]</span>
</dd>
<dt>•</dt>
<dd>Radiation recall <span class="Italics">[see Warnings and Precautions (<a href="#ID_5feef2e2-7a80-4d8e-8158-21bd42b4a3fe">5.6</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_7d61d67f-8a3b-4c9a-9882-69717ec1b859">5.7</a>)]</span>
</dd>
</dl>
<p>Postmarketing Experience</p>
<p>The following adverse reactions have been identified during postapproval use of hydroxyurea. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.</p>
<dl>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>-like skin changes, peripheral and facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyperpigmentation, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of skin and nails, scaling, violet <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Renal and urinary disorders:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, elevations in serum uric acid, blood urea nitrogen (BUN), and creatinine levels</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">General Disorders:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Hepatobiliary disorders:</span> elevation of hepatic enzymes</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>:</span> diffuse pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span></dd>
</dl>
<p>Adverse reactions observed with combined hydroxyurea and irradiation therapy are similar to those reported with the use of hydroxyurea or radiation treatment alone. These effects primarily include <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>), <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>. Almost all patients receiving an adequate course of combined hydroxyurea and irradiation therapy will demonstrate concurrent <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. Platelet <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (&lt;100,000 cells/mm<span class="Sup">3</span>) has occurred in the presence of marked <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. Hydroxyurea may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_c8dd47b0-de65-4fce-b62c-610c62668bae"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_235485ba-dc36-4583-b320-e58bc6ffb1bc"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have occurred. Hydroxyurea is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>; however, if patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is recommended. Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p>Hepatotoxicity</p>
<p>Hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported during postmarketing surveillance in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> treated with hydroxyurea and other antiretroviral drugs. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. Avoid this combination.</p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, which was severe in some cases, has been reported in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a2fb1f84-d4c0-4165-b1fb-c6447a1ee41a"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Test Interference  </h2>
<p class="First">Interference with Uric Acid, Urea, or Lactic Acid Assays</p>
<p>Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering falsely elevated results of these in patients treated with hydroxyurea.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_79e8c1e0-031c-4489-ac91-f9f985790821"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_774fe160-e26e-48e2-8aa3-27c7a102b02a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<p class="First"><span class="Italics">Teratogenic Effects</span></p>
<p>Pregnancy Category D</p>
<p><span class="Italics">Risk Summary</span></p>
<p>Hydroxyurea can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.</p>
<p>Drugs which affect DNA synthesis, such as hydroxyurea, may be potential mutagenic agents.</p>
<p>The physician should carefully consider this possibility before administering this drug to male or female patients who may contemplate conception <span class="Italics">[see Warnings and Precautions (<a href="#ID_4a7508a5-d905-4bb7-a0c6-35bd5ea4d212">5.3</a>)]</span>.</p>
<p><span class="Italics">Animal Data</span></p>
<p>Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m<span class="Sup">2</span> basis. Hydroxyurea is embryotoxic and causes <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (partially ossified cranial bones, absence of eye sockets, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span>. Hydroxyurea crosses the placenta. Single doses of ≥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) to rats caused <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and impaired learning ability.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_8b944199-fd11-473b-b591-9a75982add06"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers </h2>
<p class="First">Hydroxyurea is excreted in human milk. Because of the potential for serious adverse reactions with hydroxyurea, discontinue nursing during treatment with hydroxyurea.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_acfbcd4e-eb37-4f8b-93cb-6cf07ce72bfa"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_e8b6ccf0-5c21-49e9-99cb-a1f9948e99dd"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First">Elderly patients may be more sensitive to the effects of hydroxyurea, and may require a lower dose regimen. Hydroxyurea is excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <span class="Italics">[see Dosage and Administration (<a href="#ID_25535eeb-7735-4a2e-a6c1-0b8474a634d7">2.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_58743593-2210-41c0-aaf8-a7480ec8daaf"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </h2>
<p class="First">The exposure to hydroxyurea is higher in patients with creatinine clearance of less than 60 mL/min or in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD). Reduce dosage and closely monitor the hematologic parameters when hydroxyurea is to be administered to these patients <span class="Italics">[see Dosage and Administration (<a href="#ID_58743593-2210-41c0-aaf8-a7480ec8daaf">2.3</a>) and Clinical Pharmacology (<a href="#ID_1dced693-5a21-4167-b7b4-6df5fe635fa3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_156afb45-9fed-448a-9668-b65c2ebbdb22"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>  </h2>
<p class="First">There are no data that support specific guidance for dosage adjustment in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Close monitoring of hematologic parameters is advised in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_d2dcad8b-196e-48ad-856c-75fa8611d990"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<p class="First">Acute mucocutaneous toxicity has been reported in patients receiving hydroxyurea at dosages several times the therapeutic dose. Soreness, violet <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> on palms and soles followed by scaling of hands and feet, severe generalized hyperpigmentation of the skin, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> have also been observed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_cb7cacc4-4761-4271-a562-890bbb7f6b03"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION </h1>
<p class="First">Hydroxyurea Capsules USP are an antineoplastic agent available for oral use as capsules providing 500 mg hydroxyurea, USP. Inactive ingredients: anhydrous citric acid, benzyl alcohol, black iron oxide, butylparaben, carboxymethylcellulose sodium, D &amp; C red no. 28, D &amp; C yellow no. 10 aluminum lake, dibasic sodium phosphate, edetate calcium disodium, FD &amp; C blue no. 1, FD &amp; C blue no. 1 aluminum lake, FD &amp; C blue no. 2 aluminum lake, FD &amp; C red no. 40, FD &amp; C red no. 40 aluminum lake, gelatin, lactose monohydrate, magnesium stearate, methylparaben, pharmaceutical glaze, propylparaben, propylene glycol, red iron oxide, sodium lauryl sulfate, sodium propionate, and titanium dioxide.</p>
<p>Hydroxyurea is an essentially tasteless, white crystalline powder. Its structural formula is:</p>
<div class="Figure">
<a name="id388"></a><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b9514ae5-79ae-4cc2-9d7f-c8f7806d1694&amp;name=image-01.jpg"><p class="MultiMediaCaption">CH<span class="Sub">4</span>N<span class="Sub">2</span>O<span class="Sub">2</span>    M.W. 76.05 </p>
</div>
<p>CH<span class="Sub">4</span>N<span class="Sub">2</span>O<span class="Sub">2</span>    M.W. 76.05 </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_4ff8af4c-893b-4522-ba08-f2e3883de85f"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_f35d8c6c-3244-4103-bb52-76b349376f2d"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action </h2>
<p class="First">The precise mechanism by which hydroxyurea produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in tissue culture in rats and humans lend support to the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. This hypothesis explains why, under certain conditions, hydroxyurea may induce teratogenic effects.</p>
<p>Three mechanisms of action have been postulated for the increased effectiveness of concomitant use of hydroxyurea therapy with irradiation on squamous cell (epidermoid) carcinomas of the head and neck. <span class="Italics">In vitro</span> studies utilizing Chinese hamster cells suggest that hydroxyurea (1) is lethal to normally radioresistant S-stage cells, and (2) holds other cells of the cell cycle in the G1 or pre-DNA synthesis stage where they are most susceptible to the effects of irradiation. The third mechanism of action has been theorized on the basis of <span class="Italics">in vitro</span> studies of HeLa cells. It appears that hydroxyurea, by inhibition of DNA synthesis, hinders the normal repair process of cells damaged but not killed by irradiation, thereby decreasing their survival rate; RNA and protein syntheses have shown no alteration.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_1dced693-5a21-4167-b7b4-6df5fe635fa3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<p class="First">Absorption</p>
<p>Following oral administration of hydroxyurea, hydroxyurea reaches peak plasma concentrations in 1 to 4 hours. Mean peak plasma concentrations and AUCs increase more than proportionally with increase of dose.</p>
<p>There are no data on the effect of food on the absorption of hydroxyurea.</p>
<p>Distribution</p>
<p>Hydroxyurea distributes throughout the body with a volume of distribution approximating total body water.</p>
<p>Hydroxyurea concentrates in leukocytes and erythrocytes.</p>
<p>Metabolism</p>
<p>Up to 60% of an oral dose undergoes conversion through saturable hepatic metabolism and a minor pathway of degradation by urease found in intestinal bacteria.</p>
<p>Excretion</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span>, the mean cumulative urinary recovery of hydroxyurea was about 40% of the administered dose.</p>
<p>Specific Populations</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of hydroxyurea was assessed in adult patients with <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell disease</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with normal renal function (creatinine clearance [CrCl] &gt;80 mL/min), mild (CrCl 50 to 80 mL/min), moderate (CrCl = 30 to &lt;50 mL/min), or severe (&lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> received a single oral dose of 15 mg/kg hydroxyurea. Patients with ESRD received two doses of 15 mg/kg separated by 7 days; the first was given following a 4-hour hemodialysis session, the second prior to hemodialysis. The exposure to hydroxyurea (mean AUC) in patients with CrCl &lt;60 mL/min and those with ESRD was 64% higher than in patients with normal renal function (CrCl &gt;60 mL/min). Reduce the dose of hydroxyurea when it is administered to patients with creatinine clearance of &lt;60 mL/min or with ESR<span class="Italics">D following hemodialysis</span><span class="Italics">[see Dosage and Administration (<a href="#ID_25535eeb-7735-4a2e-a6c1-0b8474a634d7">2.3</a>) and Use in Specific Populations (<a href="#ID_58743593-2210-41c0-aaf8-a7480ec8daaf">8.6</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_4191a0d4-6028-4af4-b404-f15a5a5d86f9"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_9662714a-99f7-4682-b4e2-9c63a058a881"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First">See <span class="Italics">Warnings and Precautions</span> (<span class="Italics"><a href="#ID_ffff24db-cd61-4c2c-8e2c-a48e7769dcaf">5.2</a></span>) for carcinogenesis and mutagenesis information.</p>
<p>Conventional long-term studies to evaluate the carcinogenic potential of hydroxyurea have not been performed. However, intraperitoneal administration of 125 to 250 mg/kg hydroxyurea (about 0.6 to1.2 times the maximum recommended human oral daily dose on a mg/m<span class="Sup">2</span> basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control. Hydroxyurea is mutagenic <span class="Italics">in vitro</span> to bacteria, fungi, protozoa, and mammalian cells. Hydroxyurea is clastogenic <span class="Italics">in vitro</span> (hamster cells, human lymphoblasts) and <span class="Italics">in vivo</span> (SCE assay in rodents, mouse micronucleus assay). Hydroxyurea causes the transformation of rodent embryo cells to a tumorigenic phenotype.</p>
<p><span class="Italics">Impairment of Fertility:</span> Hydroxyurea administered to male rats at 60 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m<span class="Sup">2</span> basis) produced <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, decreased spermatogenesis, and significantly reduced their ability to impregnate females.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_4736cd56-1d67-4863-9798-868a6e917de0"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES </h1>
<p class="First">OSHA. <span class="Underline"><a href="http://www.osha.gov/SLTC/hazardousdrugs/index.html">http://www.osha.gov/SLTC/hazardousdrugs/index.html</a></span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_9488ae2b-543e-4e98-af28-986e454128ff"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16813526-423f-4933-9308-ccdf12bcd458"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied </h2>
<p class="First">Hydroxyurea Capsules USP 500 mg are available as a two-piece hard gelatin capsule with purple opaque cap and pink opaque body filled with white powder, imprinted in black ink <span class="Bold">barr 882 </span>and packaged in bottles of 100 capsules (NDC 0555-0882-02).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a3219205-9a30-41cb-9c19-100bce9f8126"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage </h2>
<p class="First">Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>STORE IN A DRY ATMOSPHERE AND AVOID EXCESSIVE HEAT.</p>
<p>WEAR GLOVES AT ALL TIMES WHEN HANDLING CONTAINERS.</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7bf426c2-7b27-4f9f-ae84-6293b12fcc24"></a><a name="section-14.3"></a><p></p>
<h2>16.3 Handling and Disposal </h2>
<p class="First">Hydroxyurea Capsules USP are a cytotoxic drug. Follow applicable special handling and disposal procedures <span class="Italics">[see References (<a href="#ID_4736cd56-1d67-4863-9798-868a6e917de0">15</a>)]</span>.</p>
<p>To decrease the risk of contact, advise caregivers to wear disposable gloves when handling Hydroxyurea Capsules USP or bottles containing Hydroxyurea Capsules USP. Wash hands with soap and water before and after contact with the bottle or capsules when handling Hydroxyurea Capsules USP. Do not open Hydroxyurea Capsules USP. Avoid exposure to crushed or opened capsules. If contact with crushed or opened capsules occurs on the skin, wash affected area immediately and thoroughly with soap and water. If contact with crushed or opened capsules occurs on the eye(s), the affected area should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> thoroughly with water or isotonic eyewash designated for that purpose for at least 15 minutes. If the powder from the capsule is spilled, immediately wipe it up with a damp disposable towel and discard in a closed container, such as a plastic bag; as should the empty capsules. The spill areas should then be cleaned three times using a detergent solution followed by clean water. Keep the medication away from children and pets. Contact your doctor for instructions on how to dispose of outdated capsules.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_018ebb53-fcaa-4bb7-a3e6-b66f1b69a2c3"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<dl>
<dt>•</dt>
<dd>There is a risk of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Monitoring blood counts weekly throughout the duration of therapy should be emphasized to patients taking hydroxyurea <span class="Italics">[see Warnings and Precautions (<a href="#ID_8cf8d7bb-eead-414c-ad39-5bdec54690f5">5.1</a>)]</span>. Advise patients to report signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> immediately.</dd>
<dt>•</dt>
<dd>Advise patients that there is a risk of cutaneous vasculitic toxicities and secondary malignancies including <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and skin cancers <span class="Italics">[see Warnings and Precautions (<a href="#ID_ffff24db-cd61-4c2c-8e2c-a48e7769dcaf">5.2</a>, <a href="#ID_cc4f0ff7-91b9-43da-a0fb-bb66711b6a4e">5.4</a>)]</span>.</dd>
<dt>•</dt>
<dd>Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy. Advise females and males of reproductive potential to use contraception during and after treatment with hydroxyurea <span class="Italics">[see Warnings and Precautions (<a href="#ID_4a7508a5-d905-4bb7-a0c6-35bd5ea4d212">5.3</a></span><span class="Italics">) and Use in Specific Populations (<a href="#ID_774fe160-e26e-48e2-8aa3-27c7a102b02a">8.1</a>)]</span>.</dd>
<dt>•</dt>
<dd>Advise females to discontinue breastfeeding during treatment with hydroxyurea <span class="Italics">[see Use in Specific Populations (<a href="#ID_8b944199-fd11-473b-b591-9a75982add06">8.3</a>)]</span>.</dd>
<dt>•</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> should contact their physician for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, hepatic events, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> <span class="Italics">[see Warnings and Precautions (<a href="#ID_e8331670-7dd8-4a03-bf7e-7dceddc202cf">5.5</a>)]</span>.</dd>
<dt>•</dt>
<dd>Postirradiation <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> can occur in patients who have received previous irradiation therapy <span class="Italics">[see Warnings and Precautions (<a href="#ID_5feef2e2-7a80-4d8e-8158-21bd42b4a3fe">5.6</a>)]</span>.</dd>
</dl>
<p class="First"><span class="Bold">TEVA PHARMACEUTICALS USA, INC.</span></p>
<p>North Wales, PA 19454</p>
<p>Rev. B 7/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f0a4d5e4-cb0c-4378-aab9-330d7fea6db4"></a><a name="section-16"></a><p></p>
<h1>Package/Label Display Panel </h1>
<div class="Figure">
<a name="id782983260"></a><img alt="Hydroxyurea Capsules USP 500 mg 100s Label " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b9514ae5-79ae-4cc2-9d7f-c8f7806d1694&amp;name=image-02.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d742422d-55e4-4fa5-97bf-d1a85c35de65"></a><a name="section-16.1"></a><p></p>
<h2>Hydroxyurea Capsules USP 500 mg 100s Label Text </h2>
<p class="First"><span class="Bold">NDC </span>0555<span class="Bold">-0882</span>-02</p>
<p><span class="Bold">HYDROXYUREA<br>Capsules USP<br>500 mg</span></p>
<p><span class="Bold">Caution: Cytotoxic, Special<br>Handling Procedures</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 CAPSULES</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDROXYUREA 		
					</strong><br><span class="contentTableReg">hydroxyurea capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0555-0882</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROXYUREA</strong> (HYDROXYUREA) </td>
<td class="formItem">HYDROXYUREA</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE CALCIUM DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PROPIONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE, PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">barr;882</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0555-0882-02</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">10/19/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075143</td>
<td class="formItem">10/19/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Barr Laboratories Inc.
							(802716563)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8b97d657-abab-4c19-af14-15ca84c054d3</div>
<div>Set id: b9514ae5-79ae-4cc2-9d7f-c8f7806d1694</div>
<div>Version: 8</div>
<div>Effective Time: 20150827</div>
</div>
</div> <div class="DistributorName">Barr Laboratories Inc.</div></p>
</body></html>
